EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Lurbinectedin in small cell lung cancer: real‐world experience of a multicentre national early access programme

Marliese Alexander iD, Jennifer Rogers, Sagun Parakh, Paul Mitchell, Timothy D Clay, Steven Kao, Brett G M Hughes, Malinda Itchins, Benjamin Y Kong, Nick Pavlakis, Benjamin J Solomon, Thomas John

Internal Medicine Journal · 2024

DOI: 10.1111/imj.16348 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Internal Medicine Journal, 2024. Verfasst von Marliese Alexander und 11 weiteren Autor:innen. Beteiligte Einrichtung: Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Carbolines, Heterocyclic Compounds, 4 or More Rings. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Specialised Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Lurbinectedin is a novel oncogenic transcription inhibitor active in several cancers, including small cell lung cancer (SCLC). We aimed to describe the first Australian experience of the clinical efficacy and tolerability of lurbinectedin for the treatment of SCLC after progression on platinum‐containing therapy.

Methods

Multicentre real‐world study of individuals with SCLC initiating lurbinectedin monotherapy (3.2 mg/m 2 three‐weekly) on an early access programme between May 2020 and December 2021. Key outcomes were clinical utilisation, efficacy and tolerability. Progression‐free survival (PFS) and overall survival (OS) were calculated using the Kaplan–Meier method. Outcome data were collected within the AUstralian Registry and biObank of thoRacic cAncers (AURORA).

Results

Data were analysed for 46 individuals across seven sites. Lurbinectedin was given as second‐ (83%, 38/46) or subsequent‐ (17%, 8/46) line therapy, mostly with prior chemoimmunotherapy (87%, 40/46). We report dose modifications (17%, 8/46), interruptions/delays (24%, 11/46), high‐grade toxicities (28%, 13/46) and hospitalisations (54%, 25/46) during active treatment. The overall response rate was 33% and the disease control rate was 50%. Six‐month OS was 44% (95% confidence interval (CI): 29.0–57.1). Twelve‐month OS was 15% (95% CI: 6.5–26.8). From lurbinectedin first dose, the median PFS was 2.5 months (95% CI: 1.8–2.9) and OS was 4.5 months (95% CI: 3.5–7.2). From SCLC diagnosis, the median OS was 12.9 months (95% CI: 11.0–17.2). Individuals with a longer chemotherapy‐free interval prior to lurbinectedin had longer PFS and OS.

Conclusion

This real‐world national experience of lurbinectedin post‐platinum chemotherapy and immunotherapy for individuals with SCLC was similar to that reported in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsCarbolinesHeterocyclic Compounds, 4 or More RingsHumansMaleFemaleAgedMiddle AgedAustraliaAntineoplastic AgentsAged, 80 and overProgression-Free SurvivalTreatment OutcomeAdult

Stichwörter der Autor:innen

lurbinectedinreal‐world datareal‐world evidencesmall cell lung cancersurvival outcomes

Substanzen

PM 01183CarbolinesHeterocyclic Compounds, 4 or More RingsAntineoplastic Agents

Autor:innen und Institutionen

  • Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
  • Austin Hospital, Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
  • School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.
  • Division of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.
  • Saint John of God Subiaco Hospital, Perth, Western Australia, Australia.

ORCID-Profile: Marliese Alexander

Förderung

  • Specialised Therapeutics

Zitieren

APA

Alexander, M., Rogers, J., Parakh, S., Mitchell, P., Clay, T. D., Kao, S., Hughes, B. G. M., Itchins, M., Kong, B. Y., Pavlakis, N., Solomon, B. J., & John, T. (2024). Lurbinectedin in small cell lung cancer: real‐world experience of a multicentre national early access programme. Internal Medicine Journal. https://doi.org/10.1111/imj.16348

Vancouver

Alexander M, Rogers J, Parakh S, Mitchell P, Clay TD, Kao S, et al. Lurbinectedin in small cell lung cancer: real‐world experience of a multicentre national early access programme. Internal Medicine Journal. 2024. doi:10.1111/imj.16348

BibTeX
@article{Alexander2024,
  author = {Alexander, Marliese and Rogers, Jennifer and Parakh, Sagun and Mitchell, Paul and Clay, Timothy D and Kao, Steven and Hughes, Brett G M and Itchins, Malinda and Kong, Benjamin Y and Pavlakis, Nick and Solomon, Benjamin J and John, Thomas},
  title = {Lurbinectedin in small cell lung cancer: real‐world experience of a multicentre national early access programme},
  journal = {Internal Medicine Journal},
  year = {2024},
  doi = {10.1111/imj.16348}
}
Kostenlos starten →